Selected research
Industry Research
Neutropenia Drugs Industry Research Report 2026
Market perspective
The global Neutropenia Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Neutropenia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Neutropenia Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Neutropenia Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Neutropenia Drugs include Apotex Inc., Biogenomics Limited, Cellerant Therapeutics, Inc., Coherus BioSciences, Inc., Dr. Reddy’s Laboratories Limited, Ligand Pharmaceuticals, Inc., NAL Pharmaceuticals Ltd., Prolong Pharmaceuticals, LLC and Richter Gedeon Nyrt., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Neutropenia Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neutropenia Drugs Market by Company
Apotex Inc.
Biogenomics Limited
Cellerant Therapeutics, Inc.
Coherus BioSciences, Inc.
Dr. Reddy’s Laboratories Limited
Ligand Pharmaceuticals, Inc.
NAL Pharmaceuticals Ltd.
Prolong Pharmaceuticals, LLC
Richter Gedeon Nyrt.
Sandoz International GmbH
Neutropenia Drugs Segment by Type
Capsule
Injection
Neutropenia Drugs Segment by Application
Hospital
Clinic
Neutropenia Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neutropenia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neutropenia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neutropenia Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Neutropenia Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Neutropenia Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Neutropenia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Capsule
- Injection
Applications
- Hospital
- Clinic
Companies covered
- Apotex Inc.
- Biogenomics Limited
- Cellerant Therapeutics, Inc.
- Coherus BioSciences, Inc.
- Dr. Reddy’s Laboratories Limited
- Ligand Pharmaceuticals, Inc.
- NAL Pharmaceuticals Ltd.
- Prolong Pharmaceuticals, LLC
- Richter Gedeon Nyrt.
- Sandoz International GmbH
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Neutropenia Drugs Market Size (2021-2032)
- 2.2.2 Global Neutropenia Drugs Sales (2021-2032)
- 2.2.3 Global Neutropenia Drugs Market Average Price (2021-2032)
- 2.3 Neutropenia Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Capsule
- 2.3.3 Injection
- 2.4 Neutropenia Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Neutropenia Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Neutropenia Drugs Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Neutropenia Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Neutropenia Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Neutropenia Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Neutropenia Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Neutropenia Drugs, Product Type & Application
- 3.8 Global Manufacturers of Neutropenia Drugs, Established Date
- 3.9 Global Neutropenia Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Apotex Inc.
- 4.1.1 Apotex Inc. Company Information
- 4.1.2 Apotex Inc. Business Overview
- 4.1.3 Apotex Inc. Neutropenia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Apotex Inc. Neutropenia Drugs Product Portfolio
- 4.1.5 Apotex Inc. Recent Developments
- 4.2 Biogenomics Limited
- 4.2.1 Biogenomics Limited Company Information
- 4.2.2 Biogenomics Limited Business Overview
- 4.2.3 Biogenomics Limited Neutropenia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Biogenomics Limited Neutropenia Drugs Product Portfolio
- 4.2.5 Biogenomics Limited Recent Developments
- 4.3 Cellerant Therapeutics, Inc.
- 4.3.1 Cellerant Therapeutics, Inc. Company Information
- 4.3.2 Cellerant Therapeutics, Inc. Business Overview
- 4.3.3 Cellerant Therapeutics, Inc. Neutropenia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Cellerant Therapeutics, Inc. Neutropenia Drugs Product Portfolio
- 4.3.5 Cellerant Therapeutics, Inc. Recent Developments
- 4.4 Coherus BioSciences, Inc.
- 4.4.1 Coherus BioSciences, Inc. Company Information
- 4.4.2 Coherus BioSciences, Inc. Business Overview
- 4.4.3 Coherus BioSciences, Inc. Neutropenia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Coherus BioSciences, Inc. Neutropenia Drugs Product Portfolio
- 4.4.5 Coherus BioSciences, Inc. Recent Developments
- 4.5 Dr. Reddy’s Laboratories Limited
- 4.5.1 Dr. Reddy’s Laboratories Limited Company Information
- 4.5.2 Dr. Reddy’s Laboratories Limited Business Overview
- 4.5.3 Dr. Reddy’s Laboratories Limited Neutropenia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Dr. Reddy’s Laboratories Limited Neutropenia Drugs Product Portfolio
- 4.5.5 Dr. Reddy’s Laboratories Limited Recent Developments
- 4.6 Ligand Pharmaceuticals, Inc.
- 4.6.1 Ligand Pharmaceuticals, Inc. Company Information
- 4.6.2 Ligand Pharmaceuticals, Inc. Business Overview
- 4.6.3 Ligand Pharmaceuticals, Inc. Neutropenia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Ligand Pharmaceuticals, Inc. Neutropenia Drugs Product Portfolio
- 4.6.5 Ligand Pharmaceuticals, Inc. Recent Developments
- 4.7 NAL Pharmaceuticals Ltd.
- 4.7.1 NAL Pharmaceuticals Ltd. Company Information
- 4.7.2 NAL Pharmaceuticals Ltd. Business Overview
- 4.7.3 NAL Pharmaceuticals Ltd. Neutropenia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 NAL Pharmaceuticals Ltd. Neutropenia Drugs Product Portfolio
- 4.7.5 NAL Pharmaceuticals Ltd. Recent Developments
- 4.8 Prolong Pharmaceuticals, LLC
- 4.8.1 Prolong Pharmaceuticals, LLC Company Information
- 4.8.2 Prolong Pharmaceuticals, LLC Business Overview
- 4.8.3 Prolong Pharmaceuticals, LLC Neutropenia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Prolong Pharmaceuticals, LLC Neutropenia Drugs Product Portfolio
- 4.8.5 Prolong Pharmaceuticals, LLC Recent Developments
- 4.9 Richter Gedeon Nyrt.
- 4.9.1 Richter Gedeon Nyrt. Company Information
- 4.9.2 Richter Gedeon Nyrt. Business Overview
- 4.9.3 Richter Gedeon Nyrt. Neutropenia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Richter Gedeon Nyrt. Neutropenia Drugs Product Portfolio
- 4.9.5 Richter Gedeon Nyrt. Recent Developments
- 4.10 Sandoz International GmbH
- 4.10.1 Sandoz International GmbH Company Information
- 4.10.2 Sandoz International GmbH Business Overview
- 4.10.3 Sandoz International GmbH Neutropenia Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sandoz International GmbH Neutropenia Drugs Product Portfolio
- 4.10.5 Sandoz International GmbH Recent Developments
5 Global Neutropenia Drugs Market Scenario by Region
- 5.1 Global Neutropenia Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Neutropenia Drugs Sales by Region: 2021-2032
- 5.2.1 Global Neutropenia Drugs Sales by Region: 2021-2026
- 5.2.2 Global Neutropenia Drugs Sales by Region: 2027-2032
- 5.3 Global Neutropenia Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Neutropenia Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Neutropenia Drugs Revenue by Region: 2027-2032
- 5.4 North America Neutropenia Drugs Market Facts & Figures by Country
- 5.4.1 North America Neutropenia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Neutropenia Drugs Sales by Country (2021-2032)
- 5.4.3 North America Neutropenia Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Neutropenia Drugs Market Facts & Figures by Country
- 5.5.1 Europe Neutropenia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Neutropenia Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Neutropenia Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Neutropenia Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Neutropenia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Neutropenia Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Neutropenia Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Neutropenia Drugs Market Facts & Figures by Country
- 5.7.1 South America Neutropenia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Neutropenia Drugs Sales by Country (2021-2032)
- 5.7.3 South America Neutropenia Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Neutropenia Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Neutropenia Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Neutropenia Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Neutropenia Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Neutropenia Drugs Sales by Type (2021-2032)
- 6.1.1 Global Neutropenia Drugs Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Neutropenia Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Neutropenia Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Neutropenia Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Neutropenia Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Neutropenia Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Neutropenia Drugs Sales by Application (2021-2032)
- 7.1.1 Global Neutropenia Drugs Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Neutropenia Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Neutropenia Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Neutropenia Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Neutropenia Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Neutropenia Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Neutropenia Drugs Value Chain Analysis
- 8.1.1 Neutropenia Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Neutropenia Drugs Production Mode & Process
- 8.2 Neutropenia Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Neutropenia Drugs Distributors
- 8.2.3 Neutropenia Drugs Customers
9 Global Neutropenia Drugs Analyzing Market Dynamics
- 9.1 Neutropenia Drugs Industry Trends
- 9.2 Neutropenia Drugs Industry Drivers
- 9.3 Neutropenia Drugs Industry Opportunities and Challenges
- 9.4 Neutropenia Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst